Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response

Pharmacogenomics

Volumn 15, Issue 5, 2014, Pages 687-698

  Zajkowska, Zuzanna E ^a   Englund, Amir ^a   Zunszain, Patricia A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antidepressant; CNR1; CNR2; COX 2; FAAH; FKBP5; GR; HPA axis; IL 1 ; immune; inflammatory; polymorphism

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; ANTIDEPRESSANT AGENT;

CNR1 GENE; COX 2 GENE; DEPRESSION; DISEASE ASSOCIATION; FAAH GENE; FKBP5 GENE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GR GENE; HETEROZYGOTE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IL 1BETA GENE; IMMUNE SYSTEM; INFLAMMATION; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; TREATMENT RESPONSE; ANIMAL; GENETICS; MENTAL STRESS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; ENDOCANNABINOIDS; HUMANS; INDIVIDUALIZED MEDICINE; INFLAMMATION; STRESS, PSYCHOLOGICAL;

EID: 84899836826     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.40     Document Type: Review

References (103)

1. Anderson IM. Pharmacological treatment of unipolar depression. Curr. Top. Behav. Neurosci. 14, 263-289 (2013).
2. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37(1), 137-162 (2012)
3. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr. Top. Behav. Neurosci. 14, 135-151 (2013).
4. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch. Gen. Psychiatry 65(4), 409-415 (2008).
5. Patas K, Penninx BW, Bus BA. et al. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain. Behav. Immun. 36, 71-79 (2013).
6. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress. Anxiety 30(4), 297-306 (2013).
7. Pariante CM, Lightman SL. The HPA axis in major depression: Classical theories and new developments. Trends Neurosci. 31(9), 464-468 (2008).
8. Stetler C, Miller GE. Depression and hypothalamic-pituitary-Adrenal activation: A quantitative summary of four decades of research. Psychosom. Med. 73(2), 114-126 (2011).
9. Lopez-Duran NL, Kovacs M, George CJ. Hypothalamic-pituitary-Adrenal axis dysregulation in depressed children and adolescents: A meta-Analysis. Psychoneuroendocrinology 34(9), 1272-1283 (2009).
10. Gorzalka BB, Hill MN. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(7), 1575-1585 (2011).
11. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47 (2013).
12. Aso E, Ozaita A, Serra MA, Maldonado R. Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype. Eur. Neuropsychopharmacol. 21(1), 11-22 (2011).
13. Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol. Ther. 138(1), 18-37 (2013).
14. Denson TF, Earleywine M. Decreased depression in marijuana users. Addict. Behav. 31(4), 738-742 (2006).
15. De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: Focus on G-protein-coupled receptors and transient receptor potential channels. J. Neuroimmune Pharmacol. 5(1), 103-121 (2010).
16. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-Tetrahydrocannabinol, cannabidiol and delta9- Tetrahydrocannabivarin. Br. J. Pharmacol. 153(2), 199-215 (2008).
17. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: Cross-Talk between the eicosanoid and endocannabinoid signaling pathways. Chem. Rev. 111(10), 5899-5921 (2011).
18. Hill MN, Tasker JG. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-Adrenal axis. Neuroscience 204, 5-16 (2012).
19. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: Genetic and biochemical evidence. Neuroscience 204, 207-229 (2012).
20. Steiner MA, Marsicano G, Wotjak CT, Lutz B. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses [Internet]. Psychoneuroendocrinology 33(8), 1165-1170 (2008).
21. Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 151(10), 4811-4819 (2010).
22. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(3), 722-729 (2011).
23. Anacker C, Zunszain PA, Carvalho LA, Pariante CM The glucocorticoid receptor: Pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36(3), 415-425 (2011).
24. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 76(1), 70-81 (2012).
25. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ. Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report. Pharmacopsychiatry 41(2), 48-53 (2008).
26. Valverde O, Torrens M. CB1 receptor-deficient mice as a model for depression. Neuroscience 204, 193-206 (2012).
27. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33(1), 54-67 (2008).
28. Topol EJ, Bousser MG, Fox KA. et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial. Lancet 376(9740), 517-523 (2010).
29. Riether D. Selective cannabinoid receptor 2 modulators: A patent review 2009-present. Expert Opin. Ther. Pat. 22(5), 495-510 (2012).
30. García-Gutiérrez MS, Pérez-Ortiz JM, Gutiérrez-Adán A, Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br. J. Pharmacol. 160(7), 1773-1784 (2010).
31. Hu B, Doods H, Treede RD, Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 143(3), 206-212 (2009).
32. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 11(1), 51-62 (2010).
33. Adamczyk P, Golda A, McCreary AC, Filip M, Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J. Physiol. Pharmacol. 59(2), 217-228 (2008).
34. Vinod KY, Xie S, Psychoyos D, Hungund BL, Cooper TB, Tejani-Butt SM. Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats. PLoS ONE 7(5), e36743 (2012).
35. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug Targets 9(5), 564-573 (2010).
36. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58(9), 1017-1030 (2010).
37. Alhouayek M, Masquelier J, Muccioli GG. Controlling 2- Arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov. Today 19(3), 295-304 (2014).
38. Dowlati Y, Herrmann N, Swardfager W. et al. A meta-Analysis of cytokines in major depression. Biol. Psychiatry 67(5), 446-457 (2010).
39. De Chiara V, Motta C, Rossi S. et al. Interleukin-1b alters the sensitivity of cannabinoid CB1 receptors controlling glutamate transmission in the striatum. Neuroscience 250, 232-239 (2013).
40. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J. Clin. Invest. 111(8), 1231-1240 (2003).
41. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol. 25(3), 201-215 (2010).
42. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-Analysis. Neuropsychopharmacology 36(12), 2452-2459 (2011).
43. Maciel IS, Silva RB, Morrone FB, Calixto JB, Campos MM. Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice. PLoS ONE 8(9), e77227 (2013).
44. Zhang J, Chen C. Endocannabinoid 2-Arachidonoylglycerol protects neurons by limiting COX-2 elevation. J. Biol. Chem. 283(33), 22601-22611 (2008).
45. Hermanson DJ, Hartley ND, Gamble-George J. et al. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 16(9), 1291-1298 (2013).
46. Hill M, Kerr DM, Burke NN. et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 204, 53-63 (2012).
47. Hill MN. Introduction to the special issue on stress, emotional behavior, and the endocannabinoid system: A decade of research. Neuroscience 204, 1-4 (2012).
48. Steiner MA, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-Adrenocortical axis. Prog. Brain Res. 170(8), 397-432 (2008).
49. Wamsteeker JI, Kuzmiski JB, Bains JS. Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J. Neurosci. 30(33), 11188-11196 (2010).
50. Hill MN, McLaughlin RJ, Morrish AC. et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-Adrenal axis. Neuropsychopharmacology 34(13), 2733-2745 (2009).
51. Mitjans M, Gastó C, Catalán R, Fañanás L, Arias B. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: The role of the CNR1, CNR2 and FAAH genes. J. Psychopharmacol. 26(10), 1391-1398 (2012).
52. Mitjans M, Serretti A, Fabbri C. et al. Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology (Berl.) 227(3), 509-519 (2013).
53. Domschke K, Dannlowski U, Ohrmann P. et al. Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in major depression. Eur. Neuropsychopharmacol. 18(10), 751-759 (2008).
54. Juhasz G, Chase D, Pegg E. et al. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34(8), 2019-2027 (2009).
55. Rossi S, Buttari F, Studer V. et al. The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult. Scler. 17(3), 281-288 (2011).
56. Palermo FA, Angelini M, Cottone E. et al. Involvement of endocannabinoid CB1 receptor in the modulation of stress responses related to xenoestrogen exposure. Ann. NY Acad. Sci. 1163, 504-507 (2009).
57. Monteleone P, Bifulco M, Maina G. et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol. Res. 61(5), 400-404 (2010).
58. Agrawal A, Nelson EC, Littlefield AK. et al. Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch. Gen. Psychiatry 69(7), 732-740 (2012).
59. Onaivi ES, Ishiguro H, Gong JP. et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: From mice to human subjects. PLoS ONE 3(2), e1640 (2008).
60. Barrero FJ, Ampuero I, Morales B. et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 5(2), 135-141 (2005).
61. Lazary J, Lazary A, Gonda X. et al. Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B(8), 1118-1127 (2009).
62. Kotov R, Gamez W, Schmidt F, Watson D. Linking 'big' personality traits to anxiety, depressive, and substance use disorders: A meta-Analysis. Psychol. Bull. 136(5), 768-821 (2010).
63. Wiersma JE, Van Oppen P, Van Schaik DJ, Van Der Does AJ, Beekman AT, Penninx BW. Psychological characteristics of chronic depression: A longitudinal cohort study. J. Clin. Psychiatry 72(3), 288-294 (2011).
64. Yildiz M, Kara M, Bozdemir M. et al. Parasuicide patients in the emergency department and their relationship with cannabinoid gene polymorphism. Translational Psychiatry 2(1), e75 (2012).
65. Pardini M, Krueger F, Koenigs M. et al. Fatty-Acid amide hydrolase polymorphisms and post-Traumatic stress disorder after penetrating brain injury. Transl. Psychiatry 2, e75 (2012).
66. De Luis DA, Sagrado MG, Aller R, Izaola O, Conde R, Romero E. C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus Type 2. Diabetes Res. Clin. Pract. 88(1), 76-80 (2010).
67. Zeng J, Li J, Huang G. 385 C/A polymorphism of the fatty acid amide hydrolase gene is associated with metabolic syndrome in the Chinese Han population. Arch. Med. Sci. 7(3), 423-427 (2011).
68. Sim MS, Hatim A, Reynolds GP, Mohamed Z. Association of a functional FAAH polymorphism with methamphetamine-induced symptoms and dependence in a Malaysian population. Pharmacogenomics 14(5), 505-514 (2013).
69. Hariri AR, Gorka A, Hyde LW. et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat-And reward-related brain function. Biol. Psychiatry 66(1), 9-16 (2009).
70. Conzelmann A, Reif A, Jacob C. et al. A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional-motivational reactivity. Psychopharmacol. (Berl.) 224(4), 573-579 (2012).
71. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: A review of recent clinical studies. Brain Behav. Immun. 31, 31-47 (2013).
72. Zunszain PA, Anacker C, Cattaneo A. et al. Interleukin-1b: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37(4), 939-949 (2012).
73. Baune BT, Dannlowski U, Domschke K. et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol. Psychiatry 67(6), 543-549 (2010).
74. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Hsu CD, Liou YJ. Interleukin-1 beta-511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromol. Med. 11(4), 322-327 (2009).
75. Borkowska P, Kucia K, Rzezniczek S. et al. Interleukin-1beta promoter (-31T/C and-511C/T) polymorphisms in major recurrent depression. J. Mol. Neurosci. 44(1), 12-16 (2011).
76. Misener VL, Gomez L, Wigg KG. et al. Tagging SNP association study of the IL-1beta gene (IL1B) and childhood-onset mood disorders. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B(5), 653-659 (2009).
77. Sasayama D, Hori H, Iijima Y. et al. Modulation of cortisol responses to the DEX/CRH test by polymorphisms of the interleukin-1beta gene in healthy adults. Behav. Brain Funct. 7, 23 (2011).
78. Shao N, Feng N, Wang Y, Mi Y, Li T, Hua L. Systematic review and meta-Analysis of COX-2 expression and polymorphisms in prostate cancer. Mol. Biol. Rep. 39(12), 10997-11004 (2012).
79. Dong J, Dai J, Zhang M, Hu Z, Shen H. Potentially functional COX-2-1195G
80. Tang W, He M, Yang B, Wei K, Yin M, Zhang L. Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese. Neurol. Sci. 34(5), 695-699 (2013).
81. Su KP, Huang SY, Peng CY. et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-Alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 67(6), 550-557 (2010).
82. Galecki P, Florkowski A, Bienkiewicz M, Szemraj J. Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology. 62(2), 116-120 (2010).
83. Serretti A, Chiesa A, Calati R. et al. No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Res. 188(1), 166-169 (2011).
84. Mendlewicz J, Crisafulli C, Calati R. et al. Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. Neurosci. Lett. 516(1), 85-88 (2012).
85. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl. 1), S186-S195 (2009).
86. Claes S. Glucocorticoid receptor polymorphisms in major depression. Ann. NY Acad. Sci. 1179, 216-228 (2009).
87. Spijker AT, Van Rossum EF. Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. Ann. NY Acad. Sci. 1179, 199-215 (2009).
88. Manenschijn L, Van Den Akker EL, Lamberts SW, Van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. NY Acad. Sci. 1179, 179-198 (2009).
89. Otte C, Wüst S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA. Glucocorticoid receptor gene and depression in patients with coronary heart disease: The Heart and Soul Study-2009 Curt Richter Award Winner. Psychoneuroendocrinology 34(10), 1574-1581 (2009).
90. Lahti J, Räikkönen K, Bruce S. et al. Glucocorticoid receptor gene haplotype predicts increased risk of hospital admission for depressive disorders in the Helsinki birth cohort study. J. Psychiatr. Res. 45(9), 1160-1164 (2011).
91. Ceulemans S, De Zutter S, Heyrman L. et al. Evidence for the involvement of the glucocorticoid receptor gene in bipolar disorder in an isolated northern Swedish population. Bipolar Disord. 13(7-8), 614-623 (2011).
92. Bet PM, Penninx BW, Bochdanovits Z. et al. Glucocorticoid receptor gene polymorphisms and childhood adversity are associated with depression: New evidence for a gene-environment interaction. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B(5), 660-669 (2009).
93. Menke A, Klengel T, Rubel J. et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 12(3), 289-296 (2013).
94. Guidotti G, Calabrese F, Anacker C, Racagni G, Pariante CM, Riva MA. Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: Modulation by antidepressant treatment. Neuropsychopharmacology 38(4), 616-627 (2013).
95. Cattaneo A, Gennarelli M, Uher R. et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38(3), 377-385 (2013).
96. Lekman M, Laje G, Charney D. et al. The FKBP5-gene in depression and treatment response-An association study in the Sequenced Treatment Alternatives to Relieve Depression (STARD) Cohort. Biol. Psychiatry 63(12), 1103-1110 (2008).
97. Zou YF, Wang F, Feng XL. et al. Meta-Analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484(1), 56-61 (2010).
98. Kirchheiner J, Lorch R, Lebedeva E. et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9(7), 841-846 (2008).
99. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: A comprehensive meta-Analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 183-194 (2013).
100. Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 153B(2), 554-560 (2010).
101. Brent D, Melhem N, Ferrell R. et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am. J. Psychiatry 167(2), 190-197 (2010).
102. Horstmann S, Lucae S, Menke A. et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3), 727-740 (2010).
103. Di Marzo V. The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60(2), 77-84 (2009).